Converting patients from warfarin to non-vitamin K antagonist oral anticoagulants

被引:0
|
作者
Romanelli, Sarah [1 ,2 ]
Rivera, Veronica [1 ]
机构
[1] Mt Sinai Hosp, Martha Stewart Ctr Living, Brookdale Dept Geriatr & Palliat Med, New York, NY USA
[2] Mt Sinai Hosp, Martha Stewart Ctr Living, Brookdale Dept Geriatr & Palliat Med, 1468 Madison Ave,Annenberg Bldg 10th Floor Box 107, New York, NY 10029 USA
关键词
Anticoagulant; atrial fibrillation; geriatrics; primary health care; quality improvement; warfarin; ATRIAL-FIBRILLATION;
D O I
10.1097/JXX.0000000000000857
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background:Non-vitamin K antagonist oral anticoagulants (NOACs) are favorable in stroke prevention for geriatric patients with nonvalvular atrial fibrillation versus warfarin. These anticoagulants do not require international normalized ratio (INR) monitoring and have lower food/drug interactions. In addition, NOACs have risk reduction in bleeding and all-cause mortality compared with warfarin.Local problem:At a geriatric primary care practice, two registered nurses manage 88 patients on warfarin for INR monitoring. Nurse practitioners (NPs) provide oversight for warfarin titration after abnormal results. The goal of this quality-improvement project was to decrease the time spent monitoring patients on warfarin.Methods:Primary care providers and cardiologists of patients on warfarin were contacted to gain approval of transition to a NOAC. The NP reviewed patients' renal function and the indication for anticoagulation and then created a list of eligible patients for transition.Interventions:Patients eligible for transition to NOACs were contacted for their consent. The transition process included stopping warfarin, ordering apixaban, ordering INR level, educating about starting apixaban, and coordinating appropriate follow-up.Results:Of 88 patients on warfarin, 21 were eligible for conversion from warfarin to apixaban. Of these 21 patients, 66% (n = 14) consented to the conversion. Of those who were not converted to apixaban, five declined due to cost and two were lost to follow-up.Conclusion:There was a reduction in nurses' monthly monitoring of patients on warfarin by 22%. Transition to NOAC was not only beneficial for patient safety and efficacy but also reduced nursing clinical time for anticoagulation encounters.
引用
收藏
页码:380 / 385
页数:6
相关论文
共 50 条
  • [31] Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
    Thomas Gremmel
    Alexander Niessner
    Hans Domanovits
    Martin Frossard
    Gürkan Sengölge
    Barbara Steinlechner
    Thomas Sycha
    Michael Wolzt
    Ingrid Pabinger
    Wiener klinische Wochenschrift, 2018, 130 : 722 - 734
  • [32] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [33] Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory
    Blann, A. D.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2014, 71 (04) : 158 - 167
  • [34] Association between non-vitamin k antagonist oral anticoagulants or warfarin and liver injury: A cohort study
    Zhao, Jiaxi
    Blais, Joseph E.
    Chui, Celine S. L.
    Suh, In-Hye
    Chen, Esa Y. H.
    Seto, Wai-Kay
    Mok, Michael T.
    Yan, Vincent K. C.
    Lau, Wallis C. Y.
    Wong, Ian C. K.
    Chan, Esther W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 603 - 603
  • [35] Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation
    Wu, Shanshan
    Xie, Shuo
    Xu, Yingjie
    Que, Dongdong
    Yau, Tung On
    Wang, Lizi
    Huang, Yuanping
    JOURNAL OF CLINICAL NURSING, 2019, 28 (9-10) : 1839 - 1846
  • [36] Pros and Cons of Vitamin K Antagonists and Non-Vitamin K Antagonist Oral Anticoagulants
    Riva, Nicoletta
    Ageno, Walter
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2015, 41 (02): : 178 - 187
  • [37] Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction
    Lee, Ki Hong
    Park, Hyung Wook
    Cho, Jeong Gwan
    Yoon, Nam Sik
    Kim, Sung Soo
    Kim, Mi Ran
    Kim, Min Chul
    Cho, Kyung Hoon
    Kim, Hyun Kuk
    Kim, Cheol Hwan
    Kim, Kyung Hwan
    Jun, Seung Jin
    Kim, Woo Jin
    Lee, Kyoung Jin
    Jeong, Hae Chang
    Cho, Jae Yeong
    Park, Keun-Ho
    Sim, Doo Sun
    Yoon, Hyun Ju
    Kim, Kye Hun
    Hong, Young Joon
    Kim, Ju Han
    Ahn, Youngkeun
    Jeong, Myung Ho
    Park, Jong Chun
    EUROPACE, 2015, 17 : 69 - 75
  • [38] Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
    Madzak, Aida
    Larsen, Torben Bjerregaard
    Lane, Deirdre A.
    Lip, Gregory Y. H.
    Nielsen, Peter Bronnum
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (10) : 1155 - 1163
  • [39] Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
    Liao, Jo-Nan
    Chan, Yi-Hsin
    Kuo, Ling
    Tsai, Chuan-Tsai
    Lim, Su-Shen
    Chao, Tze-Fan
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [40] A COMPARISON OF KIDNEY FUNCTION DECLINE IN ATRIAL FIBRILLATION PATIENTS TREATED WITH NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS OR WARFARIN
    Yao, Xiaoxi
    Tangri, Navdeep
    Sangaralingham, Lindsey
    Shah, Nilay
    Noseworthy, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 2568 - 2568